Fiche publication
Date publication
octobre 2024
Journal
Frontiers in immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GROS Frédéric
Tous les auteurs :
Le Tallec E, Bellamri N, Lelong M, Morzadec C, Frenger Q, Ballerie A, Cazalets C, Lescoat A, Gros F, Lecureur V
Lien Pubmed
Résumé
Systemic sclerosis (SSc) is an autoimmune disease characterized by antinuclear antibody production, which has been linked to an excess of apoptotic cells, normally eliminated by macrophages through efferocytosis. Additionally, circulating levels of CXCL4, a novel SSc biomarker, correlate with more severe fibrotic manifestations of the disease. Considering the defective efferocytosis of macrophages in SSc and the CXCL4-related M4 macrophage phenotype, we hypothesized that CXCL4 could be involved in the alteration of phagocytic functions of macrophages in SSc, including LC3-associated phagocytosis (LAP), another phagocytic process requiring autophagy proteins and contributing to immune silencing.
Mots clés
CXCL4, efferocytosis, fibrosis, macrophage, phagocytosis, systemic sclerosis
Référence
Front Immunol. 2024 10 11;15:1468821